Showing 2081-2090 of 5623 results for "".
- SignaBlok Receives Orphan Drug Designation From FDA for a First-in-Class TREM-1 Peptide Inhibitor for the Treatment of Retinopathy of Prematurityhttps://modernod.com/news/signablok-receives-orphan-drug-designation-from-fda-for-a-first-in-class-trem-1-peptide-inhibitor-for-the-treatment-of-retinopathy-of-prematurity/2486398/Key Takeaways The FDA granted Orphan Drug Designation to SignaBlok’s triggering receptor expressed on myeloid cells 1 peptide inhibitor for treating retinopathy of prematurity According to the company, the designation highlights the therapy’s potential as a
- TP-03 Now Approved in China for the Treatment of Demodex Blepharitishttps://modernod.com/news/tp-03-now-approved-in-china-for-the-treatment-of-demodex-blepharitis/2486355/Key Takeaways TP-03 (XDEMVY) has been approved in China by the NMPA for treating Demodex blepharitis, marking a major expansion beyond th
- Study Links Vitamin D Deficiency to Higher Risk of Dry Eye Diseasehttps://modernod.com/news/study-links-vitamin-d-deficiency-to-higher-risk-of-dry-eye-disease/2486076/Key Takeaways A large retrospective cohort study found that adults with vitamin D deficiency had a significantly higher risk of developing dry eye
- FDA Approves Yuvezzi, First Dual-Agent Eye Drop for Presbyopiahttps://modernod.com/news/fda-approves-yuvezzi-first-dual-agent-eye-drop-for-presbyopia/2485503/Tenpoint Therapeutics announced that the FDA has approved Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for the treatment of presbyopia in adults. Previously known as Brimochol PF, Yuvezzi is the first and only FDA-approved dual-agent
- Centre for Sight Launches 'Eye Health MOT' to Support Early Detection and Long-Term Vision Carehttps://modernod.com/news/centre-for-sight-launches-eye-health-mot-to-support-early-detection-and-long-term-vision-care/2485486/Centre for Sight has launched a new 'Eye Health MOT' service for people aged 40 and over, designed to offer a comprehensive, consultant-led assessment to detect early signs of eye disease before symptoms appear. According to C
- WAVE Eye Care Announces New Integration Between Topcon MYAH and WAVE Lens Designer Softwarehttps://modernod.com/news/wave-eye-care-announces-new-integration-between-topcon-myah-and-wave-lens-designer-software/2485329/At the Global Specialty Lens Symposium (GSLS) in Las Vegas, WAVE Eye Care announced a integration between the Topcon MYAH and WAVE Lens Designer Software designed to streamline the specialty contact lens fitting and design process for eye care practitioners.
- Celularity Enters Strategic Partnership with DefEYE to Advance Regenerative Therapies in Eye Carehttps://modernod.com/news/celularity-enters-strategic-partnership-with-defeye-to-advance-regenerative-therapies-in-eye-care/2484300/Celularity announced a strategic partnership with DefEYE, a newly established ophthalmic product and technology company. Under the terms of the agreement, Celularity has executed an exclusive license and pricing arrangement with DefEYE, following Celularity&rs
- The Vision Council Urges Commerce Department to Exclude Optical Products from Potential Tariffshttps://modernod.com/news/the-vision-council-urges-commerce-department-to-exclude-optical-products-from-potential-tariffs/2484295/The Vision Council has submitted formal comments to the US Department of Commerce opposing potential new tariffs that could affect essential optical products and equipment. The comments respond to two ongoing Section 2
- Locus Biosciences Announces Collaboration with Viatris to Develop Antibacterial Therapies for Ophthalmic Infectionshttps://modernod.com/news/locus-biosciences-announces-collaboration-with-viatris-to-develop-antibacterial-therapies-for-ophthalmic-infections/2484292/Locus Biosciences announced a research collaboration agreement with Viatris to develop novel engineered bacteriophage therapies targeting ophthalmic bacterial infections. While financial terms of the deal were not disc
- NEJM Publishes Study Demonstrating Vision Restoration with Brain-Computer Interface Retinal Implanthttps://modernod.com/news/nejm-publishes-study-demonstrating-vision-restoration-with-brain-computer-interface-retinal-implant/2484211/The New England Journal of Medicine (NEJM) published results from a clinical trial demonstrating that Science Corporation’s PRIMA brain-computer interface (BCI) retinal implant can restore functional